GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax
Language English Country Greece Media print-electronic
Document type Journal Article
PubMed
27572939
DOI
10.3892/ijo.2016.3596
Knihovny.cz E-resources
- MeSH
- GTP Phosphohydrolases genetics MeSH
- Indoles MeSH
- Nuclear Proteins antagonists & inhibitors metabolism MeSH
- Humans MeSH
- Melanoma drug therapy genetics metabolism MeSH
- Membrane Proteins genetics MeSH
- Mutation MeSH
- Cell Line, Tumor MeSH
- Cell Proliferation drug effects MeSH
- Zinc Finger Protein Gli2 MeSH
- Antineoplastic Agents pharmacology MeSH
- Proto-Oncogene Proteins B-raf genetics MeSH
- Pyridines pharmacology MeSH
- Pyrimidines pharmacology MeSH
- Pyrroles pharmacology MeSH
- Drug Synergism MeSH
- Kruppel-Like Transcription Factors antagonists & inhibitors metabolism MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- BRAF protein, human MeSH Browser
- GANT 61 MeSH Browser
- GLI2 protein, human MeSH Browser
- GTP Phosphohydrolases MeSH
- Indoles MeSH
- Nuclear Proteins MeSH
- Membrane Proteins MeSH
- NRAS protein, human MeSH Browser
- obatoclax MeSH Browser
- Zinc Finger Protein Gli2 MeSH
- Antineoplastic Agents MeSH
- Proto-Oncogene Proteins B-raf MeSH
- Pyridines MeSH
- Pyrimidines MeSH
- Pyrroles MeSH
- Kruppel-Like Transcription Factors MeSH
MEK kinase inhibitors (trametinib and selumetinib) or kinase inhibitors directed against mutated BRAF(V600E) (vemurafenib and dabrafenib) have initial encouraging effects in the treatment of melanoma but acquired resistance appears almost invariably after some months. Studies revealed mutually exclusive NRAS and BRAF activating mutations driving the MAPK/ERK pathway among human melanomas. Although combination therapy exerts significantly better antitumor cell efficacy, complete remission is rarely achieved. To employ an alternative approach, we have targeted the Hedgehog/GLI pathway, which is deregulated in melanomas, through the GLI1/2 inhibitor GANT61, alone or accompanied with the treatment by the BCL2 family inhibitor obatoclax in 9 melanoma cell lines. Thus, we targeted melanoma cells irrespective of their NRAS or BRAF mutational status. After GANT61 treatment, the cell viability was drastically diminished via apoptosis, as substantial nuclear DNA fragmentation was detected. In all tested melanoma cell lines, the combined treatment was more efficient than the application of each drug alone at the end of the cell growth with inhibitors. GANT61 was efficient also alone in most cell lines without the addition of obatoclax, which had only a limited effect when used as a single drug. In most cell lines, tumor cells were eradicated after 5-9 days of combined treatment in colony outgrowth assay. To conclude, GANT61 treatment might become a hopeful and effective anti-melanoma targeted therapy, especially when combined with the BCL2 family inhibitor obatoclax.
References provided by Crossref.org
The Hedgehog/GLI signaling pathway activates transcription of Slug (Snail2) in melanoma cells
Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas